Search PubMed⌕ Search

Biomedical subjects

P Naumann

Publications and source records attributed to P Naumann.

At least 19 recordsLinked to original sources
PubMed1992

[Diphtheria immunity in school beginners and after reimmunization with d-vaccine].

The antitoxin immune status against diphtheria was determined in 814 children, aged 6-7 years, 5-6 years after first immunization. All children were then re-immunized with d-vaccine. 4-8 weeks later antitoxin was again measured to assess the immunogenic effect of the booster injection (reduced toxoid dosage of 5 IU/0.5 ml). Although all children had been completely immunized as infants, 149 of them (18.3%) presented inadequate or no immunity to diphtheria. The booster injection resulted in a reliably protective antibody concentration of 0.1 IU/ml serum even in children with low or no longer demonstrable residual immunity. The high proportion of inadequately protected children and the further continual loss of antitoxin antibodies makes booster injection mandatory at the time of beginning school as well as in juveniles and adults. The Standing Immunization Commission of the Federal German Health Office recommends this re-immunization every 10 years in the form of combined tetanus-diphtheria immunization with Td vaccine.

Child↗
PubMed1979

[Present-day serological diagnosis of syphilis: comparison of TPHA and FTA-ABS tests with classical flocculation and complement-fixation reaction (author's transl)].

Twelve laboratories in the north Rhine-Westphalia participated in comparing TPHA and FTA-ABS tests with the so-called classical syphilis reactions (VDRL test, cardiolipin and pallida complement-fixation reaction, as well as Meinicke clearing reaction II). TPHA and FTA-ABS tests proved to be superior to the conventional methods both as regards specificity and sensitivity. Present-day serological tests of syphilis can thus be limited to the TPHA test to exclude syphilis, the FTA-ABS test as a confirmatory reaction and the VDRL test to judge the need or effectiveness of antisyphilitic treatment. These reactions which supersede the conventional syphilis tests serve for rational, reliable and cheap serological diagnosis of syphilis.

Cardiolipins↗
PubMed1976

[Sisomicin versus gentamicin. A comparison of antibacterial and pharmacokinetic properties (author's transl)].

In a comparison of the antibacterial in-vitro activity of sisomicin, gentamicin, and tobramycine, sisomicin showed a higher activity against E. coli, indole-positive Proteus spp. and organisms of the Klebsiella-Enterobacter-Serratia group, whereas tobramycine was superior against Pseudomonas spp. However, the differences in activity between sisomicin and gentamicin were only within one step of dilution which is hardly sufficient to guarantee a basic superiority of one or the other preparation for clinical purposes. In 12 healthy probands serum levels and renal elimination of sisomicin and gentamicin after a single intramuscular injection of 1 mg/kg body weight were investigated in a randomised change-over trial. With corresponding serum levels, almost identical elimination half-lives of 109 and 111 minutes, and recovery values of 84 and 88.4%, respectively, there were no significant differences in the pharmacokinetics of sisomicin and gentamicin. Thus in the antibacterial treatment of gentamicin-sensitive gram-negative organisms sisomicin presents an equally good alternative. With organisms only moderately sensitive or resistant to gentamicin, sisomicin, tobramycine and amikacin should be additionally tested.

Anti-Bacterial Agents↗
PubMed1976

In vitro susceptibility of clinically important bacteria to amikacin: correlation of results of broth dilution and disk sensitivity tests and effect of medium composition.

Minimal inhibitory concentrations of amikacin for 296 strains of gram-positive and gram-negative bacteria determined in Mueller-Hinton broth by the method recommended by the International Collaborative Study Group confirmed previous observations that amikacin is effective against current clinical isolates sensitive to gentamicin and that strains moderatly sensitive or resistant to gentamicin are often inhibited by clinically achievable concentrations. A simple linear regression analysis was used for comparison of zone sizes obtained with 10-mug disks of amikacin with minimal inhibitory concentrations obtained by the tube dilution technique. For 152 strains, including seven species of Enterobacteriaceae, the correleation coefficient (r) was -0.79 on Oxoid diagnostic senstivity test agar (which yields zone sizes similar to those obtained on Mueller-Hinton medium) and -0.78 on Oxoid isotonic sensitest agar (which contains cations in isotonic concentrations); the figures were -0.74 and -0.66, respectively, for 80 strains of Pseudomonas aeruginosa. Zone sizes for enteric gram-negative bacilli were on the average 2-3 mm smaller on isotonic sensitest agar than on diagnostic sensitivity test agar, and about 6 mm smaller for strains of P. aeruginosa and Providencia. Minimal inhibitory concentrations of amikacin can be estimated satisfactorily by extrapolation of results of agar diffusion tests, but the composition of the medium, particularly its calcium and magnesium content, should be defined precisely.

Amikacin↗
PubMed1976

Comparative evaluation of five aminoglycosides for treatment.

Gentamicin, tobramycin, sisomicin, amikacin and kanamycin are compared for therapeutic use by correlating the in vitro minimal inhibitory concentration with the in vivo concentration of the antibiotic attainable in the serum at half the time intervall between two administrations of the drugs. Using this method of evaluation, E. coli, Enterobacter and sensitive strains of the Klebsiella and Pseudomonas species can be treated in principle equally well with gentamicin, tobramycin and sisomicin, and to a large degree also with amikacin. Gentamicin, sisomicin and amikacin are useful against Serratia infections; but in each case, a higher dosage is needed. Within the family of aminoglycosides, sisomicin has a noteworthy activity against Enterobacter and Proteus species, while tobramycin is most outstanding against pseudomonas strains. Amikacin is especially useful against infections involving Klebsiella, Providencia and Pseudomonas strains with resistance to nearly all antibiotics including the other aminoglycosides.

Amikacin↗
PubMed1975

[Cephalosporin antibiotics from microbiologic viewpoint. A comparison of antibacterial and pharmacokinetic properties].

With the necessity not only of differentiating between effectiveness and non-effectiveness, as in the earlier phases of chemotherapy, but also of detecting graduated differences in effect quantitatively, animal experiment and clinical trial have been shown to be no longer adequate. In a correlating comparison of antibacterial activity with the drug level in vivo as the two decisive basic elements of chemotherapeutic effect, new and interesting possibilities arise for the evaluation of antibiotics. In a comparative evaluation of nine different cephalosporin antibiotics, not only the objective antibacterial and pharmacokinetic properties are taken into consideration, but also the dosage recommendations of the manufacturers as subjective factors. The result is that the cephalosporins in the treatment of gram-positive infections (except enterococci) are almost equivalent. In the gram-negative field, there are marked differences which produce a different species-dependent therapeutic value for the various preparations. A fundamentally superior "universal" cephalosporin for all bacterial infections does not exist.

Bacteria↗